Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OMO-103
- Development stage
- Phase 2
- Lead developer
- Peptomyc
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
OMO-103 is an investigational intravenous **MYC inhibitor** being developed by Peptomyc for advanced solid tumors. It is a **biologic miniprotein** composed of a 91-amino acid Omomyc-derived peptide that acts as a dominant-negative inhibitor of the MYC oncogenic transcription factor network, interfering with MYC-driven transcriptional programs that support tumor proliferation and survival. The program originated from work at the Vall d'Hebron Institute of Oncology, and early clinical data have shown a manageable safety profile, mainly low-grade infusion-related reactions, with preliminary signs of disease stabilization in heavily pretreated patients. OMO-103 is being explored in solid tumors including metastatic pancreatic cancer and osteosarcoma.
- Other names
- Omomyc miniproteinOmomyc
02
Targets
MAX (Myc-associated factor X)MYC (MYC proto-oncogene protein)
Beyond the preview
Go deeper on OMO-103.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OMO-103.